In 2022, while Pharma profits soar, a quarter of Americans struggle to pay for their prescription medicines one in three ration them as a result.ĭespite Donald Trump’s campaign promise to rein in drug companies that he said were “ getting away with murder,” he and every other Republican was silent when H.R. This consensus resembles a lone building standing after an earthquake, uniquely impervious to the polarization that has fractured so many points of former agreement. These numbers reconfirmed the existence of a decades-old supermajority committed to the proposition that government has a right and a duty to prevent drug companies from price-gouging the American people. Polls showed support ranging from 80 to an eye-popping 90-plus percent, a bipartisan firewall without analogue in American politics. To call the bill popular would be understatement. It put a hard cap on insulin prices and allowed Health and Human Services to negotiate prices on “at least” 50 of the 250 most expensive Medicare drugs. The bill reflected an intra-party compromise and disappointed progressive Democrats who had pushed for deeper reforms. 3 would allow the federal government to negotiate drug prices on behalf of Medicare, a right assumed by the governments of every other major economy. 3, was a shot across the bow of an industry accustomed to congressional docility and deference. On September 19, 2019, House Speaker Nancy Pelosi introduced the Elijah Cummings Lower Drug Costs Now Act.

Photo-Illustration: Intelligencer Photo: Getty Images

Big pharma game timing